Clinical Scorecard: Accelerated Progression of Brain Metastases After Starting Immune Checkpoint Inhibitor Therapy
At a Glance
Category
Detail
Condition
Brain metastases exhibiting hyperprogressive disease after immune checkpoint inhibitor therapy
Key Mechanisms
Immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4) enhance T-cell antitumor activity but may trigger rapid tumor growth (hyperprogressive disease) in some patients
Target Population
Cancer patients with brain metastases, primarily melanoma and non-small cell lung cancer (NSCLC) patients receiving ICI
Care Setting
Oncology and neurosurgical care settings with access to MRI imaging and immunotherapy
Key Highlights
Intracranial response rates to ICI vary: 6-25% in melanoma BM with monotherapy, up to 57% with combination therapy
Hyperprogressive disease (HPD) occurs in ~20% of BM patients treated with ICI, characterized by >2-fold increase in tumor growth rate and time-to-treatment failure <3 months
HPD is associated with poor prognosis (median overall survival ~3 months) and rapid neurological deterioration
Guideline-Based Recommendations
Diagnosis
Define HPD as time-to-treatment failure <3 months and post-ICI tumor growth rate >2 times pre-ICI growth rate
Use MRI to measure tumor volume pre- and post-ICI initiation using (AxBxC)/2 formula
Differentiate HPD from pseudoprogression via histological analysis and follow-up imaging
Management
Consider neurosurgical resection for symptomatic brain metastases
Evaluate prior radiation therapy status, as all HPD cases had prior radiation
Monitor closely for rapid tumor progression after ICI initiation to adjust treatment promptly
Monitoring & Follow-up
Perform brain MRI within 3 months before and after ICI initiation to assess tumor volume changes
Track tumor growth rate longitudinally to identify HPD early
Follow-up imaging to confirm tumor progression or regression
Risks
HPD leads to rapid tumor growth and neurological decline
Poor overall survival associated with HPD (~3 months median)
Potential for new brain metastases development as part of HPD
Patient & Prescribing Data
25 brain metastases patients (17 melanoma, 8 NSCLC) treated with PD-(L)1 or CTLA-4 inhibitors
20% developed HPD with tumor growth rate increases ranging from 4.9 to 207.7 times pre-treatment rates; prior stereotactic radiosurgery was common among HPD cases
Clinical Best Practices
Careful baseline and follow-up MRI volumetric assessment to detect HPD
Consider combination ICI therapy for improved intracranial response in asymptomatic melanoma BM patients
Integrate multidisciplinary approach including neurosurgery, radiation oncology, and medical oncology for management
Recognize HPD early to avoid delays in alternative therapeutic strategies
by Charissa A. C. Jessurun, Francesca Siddi, Noah L.A. Nawabi, Alexander F. C. Hulsbergen, Yu Tung Lo, Rohan Jha, Timothy R. Smith, Marike L. D. Broekman
